TEAD2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4792952	0.63	4/20
SCHEMBL4792411	0.66	3/20
SCHEMBL3598053	0.43	3/20
SCHEMBL6858788	0.39	3/20
SCHEMBL6211034	0.54	2/20
SCHEMBL10174986	0.48	2/20
SCHEMBL6295118	0.43	2/20
SCHEMBL2363580	0.41	2/20
SCHEMBL5775477	0.40	2/20
SCHEMBL6180515	0.40	2/20
SCHEMBL5211644	0.40	2/20
SCHEMBL5429766	0.39	2/20
Pirlindole (SCHEMBL373564)	1.00	1/20
Pirlindole (SCHEMBL4157397)	0.97	1/20
Pirlindole (SCHEMBL1649683)	0.95	1/20
SCHEMBL4152460	0.88	1/20
Pirlindole (SCHEMBL3761340)	0.85	1/20
SCHEMBL9522037	0.74	1/20
SCHEMBL10388478	0.73	1/20
Flufenamic Acid (SCHEMBL17497)	0.71	1/20

Clinical trials — most relevant to TEAD2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer	PHASE2	COMPLETED
SCARFREE-001: Verteporfin for Scar Prevention	PHASE2	NOT_YET_RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Safety and Pharmacokinetic Profile of CKD-581	PHASE1	COMPLETED
Epithelioid Haemangioendothelioma Observational Study	nan	RECRUITING
Green Tea Anticancer Mechanisms in Smokers	nan	COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Patient's Derived Organoids for Drug Screening in Glioblastoma	nan	NOT_YET_RECRUITING
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage Small Cell Lung Cancer During First-Line Chemoimmunotherapy	nan	NOT_YET_RECRUITING
EGCG Modulate the Cytotoxic Effects of Chemotherapeutic Agents in Human Urothelial Carcinoma Cells	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Evaluation of the Predictive Effect of Inflammatory Markers in MI Patients	nan	UNKNOWN
Gene Expression Variation and Implant Wound Healing Among Smokers and Diabetics	nan	COMPLETED
Assessment Of Long Noncoding RNA CCAT1 In Colorectal Cancer Patients	nan	UNKNOWN
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors	nan	UNKNOWN
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.	nan	UNKNOWN
EKLF Gene Expression in β-thalassemia	nan	NOT_YET_RECRUITING
Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes	nan	ACTIVE_NOT_RECRUITING
Family Resilience Initiative Research Program	nan	UNKNOWN
Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma	nan	UNKNOWN
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
The Role of TBX3 in Human ES Cell Differentiation	nan	WITHDRAWN
Investigation of the Genetic and Environmental Causes of Autism: a Multi-Center Study	nan	NOT_YET_RECRUITING
Epigenetic Testing for Breast Cancer Risk Stratification	nan	COMPLETED
A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC.	nan	UNKNOWN
Analysis of the Role of AIRE in Autoimmune Neurological Diseases Associated With Autoantibodies	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a TEAD2 binder may also engage these)

Protein	Name	Similarity
P48301	—	1.000	P48301 →
Q90701	—	0.991	Q90701 →
TEAD4	Transcriptional enhancer factor TEF-3	0.991	landscape →
P48984	—	0.990	P48984 →
P70210	—	0.989	P70210 →
Q8TE85	—	0.988	Q8TE85 →
NR4A1	Nuclear receptor subfamily 4immunitygroup A member 1	0.987	landscape →
Q80XS6	—	0.987	Q80XS6 →
Q9H8N7	—	0.987	Q9H8N7 →
Q62296	—	0.987	Q62296 →
PIK3C2B	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	0.986	landscape →
A1A4J7	—	0.986	A1A4J7 →
Q68EF0	—	0.986	Q68EF0 →
Q62141	—	0.986	Q62141 →
Q3UJB9	—	0.986	Q3UJB9 →
P38532	—	0.985	P38532 →
Q96C34	—	0.985	Q96C34 →
P70671	—	0.985	P70671 →
A6ND36	—	0.985	A6ND36 →
Q6PIJ4	—	0.985	Q6PIJ4 →
A2A9T0	—	0.985	A2A9T0 →
Q5FWH3	—	0.985	Q5FWH3 →
Q8BK03	—	0.984	Q8BK03 →
B9EJA2	—	0.984	B9EJA2 →
Q8AXV6	—	0.984	Q8AXV6 →
Q2IBD4	—	0.984	Q2IBD4 →
TEAD1	Transcriptional enhancer factor TEF-1	0.984	landscape →
Q3UQU0	—	0.984	Q3UQU0 →
P22829	—	0.984	P22829 →
Q6PFH3	—	0.984	Q6PFH3 →